Rutgers Expert Available to Discuss Mixing and Matching of COVID-19 Vaccines, Booster Shots

Rutgers infectious disease expert Shobha Swaminathan is available to discuss the mixing and matching of COVID-19 vaccines and boosters as the Food and Drugs Administration authorized booster shots for both the Johnson & Johnson and Moderna vaccines. “There is mounting…

10 questions you want answered on COVID-19

Should children under the age of 12 be vaccinated against COVID-19? Is it possible to achieve herd immunity? Will an 80 per cent vaccination rate keep us safe? In this video, UniSA epidemiologist Professor Adrian Esterman answers these questions and a lot more. The former World Health Organization consultant shares his expertise – 50 years’ worth – and argues for a different approach to tackling COVID-19.
https://www.youtube.com/watch?v=MLKC9q9yEto

Data and safety review board reports how it monitored the COVID-19 vaccine trials

Evaluation of three vaccine candidates during the COVID-19 pandemic fell to 12 experts of the federally appointed COVID-19 Vaccine Data and Safety Monitoring Board. This team has now taken the unusual step of publishing details of their review process in The Journal of Infectious Diseases.

6 important things to know about your COVID-19 vaccine card

Everyone who gets vaccinated for COVID-19 in the U.S. receives a vaccine card. Sarah Lynch, clinical assistant professor of pharmacy practice at Binghamton University, State University of New York, offers insight into why vaccine cards are important and why you…

George Washington University Public Health/Medical Experts Available for Media Interviews on COVID-19 Vaccine

On Dec. 17, a U.S. Food and Drug Administration panel is expected to review the data on the Moderna COVID-19 vaccine, paving the way for approval. Researchers at the George Washington University led one of the 100 clinical sites testing…

UNLV Immunologist on the Differences Between Two Leading COVID-19 Vaccine Candidates

Millions around the world have waited for news about a COVID-19 vaccine, regarding it as the beginning of the end for the global pandemic and a herald for the eventual return to “normal life.” Recent announcements from pharmaceutical companies Pfizer and Moderna that their respective late-stage vaccine trials have shown a 90% or better effectiveness rate have received international applause, excitement furthered with estimates that doses could be ready as early as December.

Rutgers Vaccine Expert Available to Discuss Moderna’s FDA Submission

Rutgers’ principal investigator for the Moderna phase 3 coronavirus vaccine clinical trial at Rutgers New Jersey Medical School is available to discuss the drugmaker’s submission of its vaccine to the U.S. Food and Drug Administration for regulatory approval. “It is…

Rutgers Infectious Disease Expert Available to Discuss Moderna’s Coronavirus Vaccine

Rutgers’ principal investigator for the Moderna phase 3 coronavirus vaccine clinical trial at Rutgers New Jersey Medical School is available to discuss the drugmaker’s vaccine, which the company has announced is 94.5 percent effective. Moderna intends to seek an emergency…